New 48-week data from the Phase IIIb APEX trial (NCT04882098) show Tremfya (guselkumab; Johnson & Johnson) produces sustained inhibition of radiographic progression and improved clinical symptoms in ...

In November 2025, Johnson & Johnson announced several major product developments, including new FDA approvals for DARZALEX ...

A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and ...

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...

In this article, we’ll explore the soulful depth of Jamaican soups that bring together the warmth of fall with the ...